Comparing the current results to its competitors, Qrons Inc reported Revenue decrease in the 4 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 10.32 %, recorded in the same quarter.
Qrons Inc 's Comment on Competition and Industry Peers
First Person operates in the Cognitive Wellness & Nootropics Market and the Functional Beverage & Alcohol Alternative Market, producing consumer nutraceutical products. Its competitors include the public company Laird Superfood, Inc., as well as various private nootropic supplement and functional beverage brands. The company utilizes proprietary functional mushroom-based supplements and ingredient innovations in its product offerings.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Anavex Life Sciences Corp's business model focuses on the development and commercialization of innovative pharmaceutical products for the treatment of central nervous system diseases.
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.
Sources:
Qrons Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Qrons Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
